|
CH652145A5
(de)
|
1982-01-22 |
1985-10-31 |
Sandoz Ag |
Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
|
|
US5672347A
(en)
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4965198A
(en)
|
1985-12-24 |
1990-10-23 |
Konica Corporation |
Monoclonal antibody and method of manufacturing hybridoma producing the same
|
|
DE3631229A1
(de)
|
1986-09-13 |
1988-03-24 |
Basf Ag |
Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
|
|
DK590387A
(da)
|
1986-11-13 |
1988-05-14 |
Otsuka Pharma Co Ltd |
Antistoffer mod interleukin-1
|
|
US5034316A
(en)
|
1987-03-30 |
1991-07-23 |
The Regents Of The University Of California |
In vitro human monoclonal IgG rheumatoid factor autoantibody
|
|
US4968607A
(en)
|
1987-11-25 |
1990-11-06 |
Immunex Corporation |
Interleukin-1 receptors
|
|
FR2640146B1
(fr)
|
1988-12-08 |
1993-12-24 |
Commissariat A Energie Atomique |
Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5407431A
(en)
|
1989-07-11 |
1995-04-18 |
Med-Design Inc. |
Intravenous catheter insertion device with retractable needle
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
GB9122820D0
(en)
|
1991-10-28 |
1991-12-11 |
Wellcome Found |
Stabilised antibodies
|
|
EP0664713B1
(en)
|
1992-10-14 |
2000-01-19 |
Nycomed Imaging As |
Therapeutic and diagnostic imaging compositions and methods
|
|
DK0614984T4
(da)
|
1993-03-05 |
2010-12-20 |
Bayer Healthcare Llc |
Humane monoklonale anti-TNF-alfa-antistoffer
|
|
US5959085A
(en)
|
1993-11-23 |
1999-09-28 |
Schering Corporation |
Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
|
|
EP0659766A1
(en)
|
1993-11-23 |
1995-06-28 |
Schering-Plough |
Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
|
|
GB9405021D0
(en)
|
1994-03-15 |
1994-04-27 |
Unilever Plc |
Skin treatment composition
|
|
GB9509620D0
(en)
|
1995-05-12 |
1995-07-05 |
Nat Blood Authority |
Transepithelial transport of molecular species
|
|
WO1997002479A2
(en)
|
1995-06-30 |
1997-01-23 |
Yale University |
Human monoclonal anti-tumor antibodies
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
SE9802402D0
(sv)
|
1998-07-03 |
1998-07-03 |
Karolinska Innovations Ab |
Method of diagnosing cardiovascular disease and early atherosclerosis
|
|
US20030040617A9
(en)
|
1999-03-12 |
2003-02-27 |
Rosen Craig A. |
Nucleic acids, proteins and antibodies
|
|
DE19943790C2
(de)
|
1999-09-13 |
2001-11-15 |
Ericsson Telefon Ab L M |
Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
|
|
US6380129B1
(en)
|
1999-11-02 |
2002-04-30 |
Richard J. Kraemer |
Enhanced materials for treatment of contamination
|
|
US6811788B2
(en)
|
2000-01-19 |
2004-11-02 |
Baofa Yu |
Combinations and methods for treating neoplasms
|
|
US20030232054A1
(en)
|
2000-01-25 |
2003-12-18 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
|
US6623736B2
(en)
|
2000-05-02 |
2003-09-23 |
Edward L. Tobinick |
Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
|
|
AU2007202323C1
(en)
|
2000-06-29 |
2012-04-12 |
Abbvie Inc. |
Dual specificity antibodies and methods of making and using
|
|
CA2426384A1
(en)
|
2000-10-19 |
2003-04-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody inhibiting vplf activity
|
|
US20030026806A1
(en)
|
2000-10-27 |
2003-02-06 |
Amgen Inc. |
Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
|
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
|
US7273888B2
(en)
|
2001-11-16 |
2007-09-25 |
Als Therapy Development Foundation, Inc. |
Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
|
|
CN100522999C
(zh)
|
2002-02-14 |
2009-08-05 |
免疫医疗公司 |
抗cd20抗体及其融合蛋白和使用方法
|
|
PL377091A1
(pl)
|
2002-09-06 |
2006-01-23 |
Amgen, Inc. |
Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
|
|
JP4450644B2
(ja)
|
2003-03-03 |
2010-04-14 |
日本化薬株式会社 |
Ａｍｆ類を有効成分とする医薬製剤
|
|
WO2004100987A2
(en)
|
2003-05-06 |
2004-11-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of using il-1 antagonists to treat neointimal hyperplasia
|
|
KR100493102B1
(ko)
|
2003-06-30 |
2005-06-02 |
삼성전자주식회사 |
서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
US7799327B2
(en)
|
2003-12-24 |
2010-09-21 |
Henry John Smith |
Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
|
|
US7105183B2
(en)
|
2004-02-03 |
2006-09-12 |
The Regents Of The University Of California |
Chlorite in the treatment of neurodegenerative disease
|
|
JP5149001B2
(ja)
|
2004-05-25 |
2013-02-20 |
スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ |
癌の処置におけるマイグラスタチンアナログ
|
|
CA2568352C
(en)
*
|
2004-06-04 |
2011-09-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of using il-1 antagonists to treat autoinflammatory disease
|
|
US20050276807A1
(en)
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of acne
|
|
WO2006036936A2
(en)
|
2004-09-27 |
2006-04-06 |
Bridge Pharma, Inc. |
The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
|
|
WO2006062779A2
(en)
|
2004-12-09 |
2006-06-15 |
Centocor, Inc. |
Anti-integrin immunoconjugates, methods and uses
|
|
CN109187944A
(zh)
|
2005-08-02 |
2019-01-11 |
埃克斯生物科技公司 |
使用IL-1α自身抗体诊断、治疗和预防血管疾病
|
|
US20090215992A1
(en)
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
KR20080047564A
(ko)
|
2005-09-28 |
2008-05-29 |
사이토스 바이오테크놀로지 아게 |
인터루킨-1 컨쥬게이트 및 그의 용도
|
|
CA2648223A1
(en)
|
2006-04-14 |
2007-10-25 |
Novartis Ag |
Use of il-i antibodies for treating ophthalmic disorders
|
|
US20110008282A1
(en)
|
2006-05-15 |
2011-01-13 |
Xbiotech, Inc. |
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
|
AU2007251239B2
(en)
|
2006-05-15 |
2013-08-22 |
Xbiotech Inc. |
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
|
PT2109623E
(pt)
|
2006-05-22 |
2012-01-12 |
Xbiotech Inc |
Tratamento de cancro com anticorpos anti-il-1
|
|
HRP20140172T1
(hr)
|
2006-05-30 |
2014-03-28 |
Genentech, Inc. |
Protutijela i imunokonjugati kao i njihove uporabe
|
|
FR2902659A1
(fr)
|
2006-06-23 |
2007-12-28 |
Pierre Fabre Medicament Sa |
Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
|
|
US8324350B2
(en)
|
2006-12-29 |
2012-12-04 |
Abbott Laboratories |
Dual-specific IL-1α/IL-1β antibodies
|
|
JP2011521896A
(ja)
|
2008-04-15 |
2011-07-28 |
サーコード コーポレイション |
免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
|
|
CN105467136B
(zh)
|
2008-05-30 |
2018-02-16 |
埃克斯生物科技公司 |
白细胞介素‑1α抗体及使用方法
|
|
WO2010030979A2
(en)
|
2008-09-12 |
2010-03-18 |
Xbiotech, Inc. |
Targeting pathogenic monocytes
|
|
ES2466341T3
(es)
|
2008-10-16 |
2014-06-10 |
Janssen Pharmaceuticals, Inc. |
Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
|
|
PE20120586A1
(es)
|
2009-01-29 |
2012-06-17 |
Abbott Lab |
Proteinas de union a il-1
|
|
TW201124427A
(en)
|
2009-10-15 |
2011-07-16 |
Abbott Lab |
IL-1 binding proteins
|
|
CN105056232A
(zh)
|
2010-06-03 |
2015-11-18 |
阿布维生物技术有限公司 |
用于治疗化脓性汗腺炎(hs)的用途和组合物
|
|
JP6324720B2
(ja)
|
2010-06-18 |
2018-05-16 |
エックスバイオテク, インコーポレイテッドXbiotech, Inc. |
関節炎治療
|
|
KR102748255B1
(ko)
|
2010-08-23 |
2024-12-31 |
엑스바이오테크 인코포레이티드 |
종양성 질병들에 대한 치료
|
|
NZ607510A
(en)
|
2010-09-10 |
2014-10-31 |
Apexigen Inc |
Anti-il-1 beta antibodies and methods of use
|
|
TR201802772T4
(tr)
*
|
2010-11-17 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
|
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
|
RU2013145283A
(ru)
*
|
2011-03-14 |
2015-04-20 |
Флого АпС |
Новые антагонисты рецептора интерлейкина-1
|
|
EP2694107B1
(en)
|
2011-04-01 |
2018-08-22 |
XBiotech, Inc |
Treatment for dermatological pathologies
|
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
|
US8790651B2
(en)
*
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
JP6204915B2
(ja)
|
2011-09-23 |
2017-09-27 |
エックスバイオテク, インコーポレイテッドXbiotech, Inc. |
悪液質治療
|
|
US20130195877A1
(en)
|
2012-01-31 |
2013-08-01 |
Xbiotech, Inc. |
Treatment of cachexia by targeting interleukin-1 beta
|
|
US9545441B2
(en)
|
2012-09-18 |
2017-01-17 |
Xbiotech, Inc. |
Treatment of diabetes
|
|
EP4628162A3
(en)
|
2012-10-04 |
2025-12-03 |
XBiotech Inc. |
Treating vascular disease and complications thereof
|
|
CA2886757C
(en)
*
|
2012-10-04 |
2022-04-05 |
Xbiotech Inc. |
Treatment of anxiety with il1.alpha. antagonist
|
|
US9809645B2
(en)
*
|
2013-03-12 |
2017-11-07 |
Zenyaku Kogyo Kabushikikaisha |
Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
|
|
US20150024031A1
(en)
|
2013-07-17 |
2015-01-22 |
Baxter International Inc. |
Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
|
|
WO2015187779A1
(en)
|
2014-06-03 |
2015-12-10 |
Xbiotech, Inc. |
Compositions and methods for treating and preventing staphylococcus aureus infections
|